More drugs may see price revisions as raw material costs, expenses rise

API prices have gone up by 25-30 per cent for some drugs in recent months

drug, medicine, pharmaceutical, pharma

NPPA has the powers under para 19 of the Drug Price Control Order, 2013 to fix ceiling prices of any drug whether or not they fall under the National List of Essential Medicines

Sohini Das Mumbai
After anti coagulant drug Heparin, pharma industry is keen to have at least another 25-30 drugs be considered for an upward price revision as raw material prices and other expenses have shot up in recent months. The include common drugs like paracetamol and some antibiotics and vitamins.

On Wednesday, the National Pharmaceutical Pricing Authority, the country's pricing regulator allowed a one time and temporary price increase of 50 per cent till December 31 this year for heparin injectable after hike in input costs and shortage of supplies from China hit the manufacturers. Heparin 5000iu/ml injection roughly costs around Rs 90-100 for a vial.

The industry had made several representations to the pricing regulator after prices of the active pharmaceutical ingredient

First Published: Jul 02 2020 | 6:56 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to